Viking Therapeutics Stock Falls Below $35 IPO Price Amid Dilution Concerns
Viking Therapeutics (NASDAQ: VKTX) has seen its stock price drop below the $35 offering price from a recent equity raise, despite strong top-line results for its weight-loss drug candidate, VK2735. The company raised over $575 million through both an additional public offering and convertible senior notes following promising maintenance study data. However, with increased share dilution due to 9 million new shares issued, the earnings per share have been reduced by approximately 14.4%, which could impact investor returns even if future earnings remain stable. The stock currently trades at $30.51 and has a market cap of around $3.9 billion. While Viking's results de-risked injectable VK2735 for maintenance dosing, the lack of data on an oral formulation remains a limitation. Analysts suggest that investors who were bullish prior to these developments may still consider buying now due to potential long-term upside. The broader market reaction has been mixed; while Viking's stock surged initially after results were released, it is currently down 6.41% as of the latest trading session.
Tickers: $VKTX
Topics: clinical-trials earnings-dilution equity-offering pharmaceuticals